Introduction {#s1}
============

The human *BEST1* gene encodes a protein (BESTROPHIN1, or BEST1) that is predominantly expressed in retinal pigment epithelium (RPE) ([@bib28]; [@bib32]; [@bib38]). To date, over 200 distinct mutations in *BEST1* have been identified to associate with bestrophinopathies (<http://www-huge.uni-regensburg.de/BEST1_database/home.php?select_db=BEST1>), which consist of at least five distinct retinal degeneration disorders, namely: Best vitelliform macular dystrophy (BVMD) ([@bib32]; [@bib38]), autosomal recessive bestrophinopathy (ARB) ([@bib5]), adult-onset vitelliform dystrophy (AVMD) ([@bib2]; [@bib24]), autosomal dominant vitreoretinochoroidopathy (ADVIRC) ([@bib54]), and retinitis pigmentosa (RP) ([@bib7]). Patients with bestrophinopathies are susceptible to progressive vision loss for which there is currently no treatment available. Therefore, understanding how disease-causing mutations affect the biological function of BEST1 in the retina is critical for elucidating the pathology of bestrophinopathies and developing rational therapeutic interventions.

A clinical feature of bestrophinopathies associated with *BEST1* mutations is abnormal electrooculogram (EOG) light peak (LP), measured by the maximum transepithelial potential produced by RPE upon light exposure ([@bib4]; [@bib30]). LP is believed to represent a depolarization of the basolateral membrane of RPE due to activation of a Cl^-^ conductance triggered by changes in intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) ([@bib11]; [@bib13]; [@bib14]). The simplest hypothesis about the origin of this ion conductance is that it is generated by Ca^2+^-activated Cl^-^ channels (CaCCs). However, the existence of Ca^2+^-dependent Cl^-^ current on the plasma membrane of RPE has not yet been directly demonstrated, let alone the identity of the participating channel(s).

BEST1 localizes to the basolateral membrane of RPE ([@bib28]), and has been functionally identified as a CaCC in heterologous expression studies ([@bib17]; [@bib20]; [@bib46]; [@bib47]; [@bib49]; [@bib53]). Consequently, whether or not BEST1 conducts Ca^2+^-dependent Cl^-^ currents responsible for LP in RPE has been a long-standing question in the field ([@bib17]; [@bib18]). *Best1* knock-out mice do not have any retinal phenotype or Cl^-^ current abnormality ([@bib29]; [@bib35]), suggesting that either BEST1 is not the Cl^-^ conducting channel in RPE, or that there are fundamental differences between humans and mice regarding the genetic bases for this electrophysiological response. So far only two studies investigated the Cl^-^ channel function of endogenous BEST1 in human RPE. Although both studies demonstrated that Cl^-^ secretions were partially impaired in iPSC-RPEs (RPE cells differentiated from induced pluripotent stem cells) derived from *BEST1* patients compared to those from healthy donors ([@bib35]; [@bib36]), whether or not the CaCC function of BEST1 is involved remains unknown. The first study measured volume-regulated Cl^-^ current without testing the involvement of Ca^2+^, and used only one WT iPSC-RPE as the control which may not be representative ([@bib18]; [@bib35]). The second study, by our group, utilized anion sensitve fluorescent dyes to detect changes in Ca^2+^-stimulated Cl^-^ secretion, which is not a direct measurement of CaCC activity ([@bib36]). As BEST1 has also been suggested to regulate intracellular Ca^2+^ homeostasis by controlling intracellular Ca^2+^ stores on the endoplasmic reticulum (ER) membrane and/or modulating Ca^2+^ entry through L-type Ca^2+^ channels ([@bib3]; [@bib6]; [@bib16]; [@bib37]; [@bib43]; [@bib45]), our observations could potentially reflect BEST1's role as a regulator of Ca^2+^ signaling rather than as a CaCC. Moreover, two recent reports argued that other CaCCs rather than BEST1 are responsible for Ca^2+^-stimulated Cl^-^ current based on results from porcine and mouse RPEs, and the human RPE-derived ARPE-19 cell line ([@bib21]; [@bib42]).

Overall, the physiological role of BEST1 in human RPE and the pathological mechanisms of *BEST1* disease-causing mutations are still poorly understood. Here for the first time, we directly measured Ca^2+^-dependent Cl^-^ currents on the plasma membrane of human RPEs by whole-cell patch clamp, evaluated the physiological influence of two distinct ARB patient-derived *BEST1* mutations in this context, and demonstrated rescue of mutation-caused loss of function by complementation. We further investigated the impacts of the two disease-causing mutations on the function and structure of BEST1 by electrophysiological and crystallographic approaches, respectively, and discovered mechanistic bases correlated with patient clinical phenotypes. Our results provide definitive evidence that the CaCC activity of BEST1 is indispensable for Ca^2+^-dependent Cl^-^ currents in human RPE, reveal the molecular mechanisms of two *BEST1* patient mutations, and offer a proof-of-concept for curing *BEST1*-associated retinal degenerative diseases.

Results {#s2}
=======

Direct recording of Ca^2+^-dependent Cl^-^ current by whole-cell patch clamp in human RPEs {#s2-1}
------------------------------------------------------------------------------------------

Reduced LP is a pathognomonic phenotype associated with *BEST1* mutations in bestrophinopathy patients ([@bib4]; [@bib30]). Although LP is believed to be mediated by surface Ca^2+^-dependent Cl^-^ current in RPE, the existence of the current on the plasma membrane of RPE cells has not been directly demonstrated, let alone the putative physiological role of BEST1 as a contributor to the current. To address these deficits, we generated iPSC-RPEs from the skin fibroblasts of two *BEST1* WT donors ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). We first examined the subcellular localization of BEST1 by fluorescent co-immunostaining of the channel together with a plasma membrane marker (zonula occludens-1, ZO-1) and a nucleus marker (Hoechst) followed by confocal microscopy. We found that BEST1 localized on the plasma membrane of iPSC-RPE ([Figure 1A](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

![Subcellular localization of BEST1 and surface Ca^2+^-dependent Cl^-^ current in *BEST1* WT donor iPSC-RPEs.\
(**A**) Confocal images showing plasma membrane localization of BEST1. Scale bar, 10 μm. (**B**) Representative current traces recorded from a *BEST1* WT donor iPSC-RPEs at various free \[Ca^2+^\]~i~. Voltage protocol used to elicit currents is shown in *Insert*. Scale bar, 1 nA, 150 ms. (**C**) Population steady-state current-voltage relationships at different free \[Ca^2+^\]~i~; n = 5--6 for each point. The plot was fitted to the Hill equation. (**D**) Ca^2+^-dependent activation of surface current. Steady-state current density recorded at +100 mV plotted vs. free \[Ca^2+^\]~i~; n = 5--6 for each point. See also [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.29914.005Figure 1---source data 1.Comparison of different data sets from the same donors.Ca^2+^-dependent Cl^-^ current amplitudes in two clonal iPSC-RPEs (for WT and I201T) or iPSC-RPEs generated by two different sets of differentiations (for P274R) from the same donors. n = 5--6 for each data set. Diff: differentiation.](elife-29914-fig1){#fig1}

We examined the Ca^2+^-dependent Cl^-^ current amplitudes on the plasma membrane of RPE using whole-cell patch clamp across a range of free \[Ca^2+^\]~i~ ([Figure 1B--D](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Currents were tiny (\< 5 pA/pF) when \[Ca^2+^\]~i~ was 0 ([Figure 1B,C](#fig1){ref-type="fig"}), and increased in amplitude as \[Ca^2+^\]~i~ was raised from 100 nM to 4.2 μM, peaking at 358 ± 15 pA/pF at 1.2 and 4.2 μM \[Ca^2+^\]~i~ ([Figure 1B--D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}, and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). The measured currents were inhibited by the Cl^-^ channel blocker niflumic acid (NFA) ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), demonstrating that these were indeed Ca^2+^-dependent Cl^-^ currents. A plot of peak current (evoked with a +100 mV step pulse) as a function of \[Ca^2+^\]~i~ displayed robust Ca^2+^-dependent activation with the half maximal effective concentration (EC~50~) of Ca^2+^ at 455 nM. Similar Ca^2+^-dependent Cl^-^ current profiles were recorded in iPSC-RPEs derived from two independent *BEST1* WT donors, and in iPSC-RPEs from two distinct clonal iPSCs of the same donor ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). These results provide the first direct measurement of Ca^2+^-dependent Cl^-^ currents on the plasma membrane of RPE.

To test if the status of BEST1 and the properties of surface Ca^2+^-dependent Cl^-^ current in iPSC-RPE represent those in real RPE, we conducted the same set of experiments in fetal human RPE (fhRPE). Consistent with the results from iPSC-RPEs, BEST1 was plasma membrane enriched ([Figure 2A](#fig2){ref-type="fig"}), and a similar pattern of Ca^2+^-dependent Cl^-^ currents was recorded in fhRPEs from two independent fetuses ([Figure 2B--E](#fig2){ref-type="fig"}). Interestingly, despite their comparable initial and peak amplitudes, the Ca^2+^-dependent Cl^-^ current in fhRPEs displayed a lower Ca^2+^ sensitivity compared to that in iPSC-RPEs (EC~50~ 1.7 μM vs. 455 nM, [Figure 2D](#fig2){ref-type="fig"}), which may reflect the different requirement of LP generation in RPE during different developmental stages. Overall, the subcellular localization of BEST1 and the properties of Ca^2+^-dependent Cl^-^ current in iPSC-RPE resemble those in fhRPE, validating iPSC-RPE as a powerful platform to study the influence of *BEST1* mutations on RPE surface Ca^2+^-dependent Cl^-^ currents.

![Subcellular localization of BEST1 and surface Ca^2+^-dependent Cl^-^ current in fhRPEs.\
(**A**) Confocal images showing plasma membrane localization of BEST1. Scale bar, 10 μm. (**B**) Representative current traces recorded from a *BEST1* WT fhRPEs at various free \[Ca^2+^\]~i~. Scale bar, 1 nA, 150 ms. (**C**) Population steady-state current-voltage relationships at different free \[Ca^2+^\]~i~; n = 5--6 for each point. (**D**) Ca^2+^-dependent activation of surface currents in fhRPE (●) and iPSC-RPE (●). Steady-state current density recorded at +100 mV plotted vs. free \[Ca^2+^\]~i~; n = 5--6 for each point. The plots were fitted to the Hill equation. (**E**) Bar chart showing the steady-state current amplitudes at 0 and 18 μM free \[Ca^2+^\]~i~ in RPEs from two distinct human fetuses; n = 5--6. ^∗\$^*p*\<0.05 compared to fetus \#1 (0.02) and \#2 (0.02), respectively, at 18 μM \[Ca^2+^\]~i~ using two-tailed unpaired Student *t* test. See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.](elife-29914-fig2){#fig2}

It is worth to note that during patch clamp recording with fhRPE, when the pipet solution contained high (18 μM) \[Ca^2+^\]~i~, the currents ran up after patch break with a half-time of \~2.5 min and reached a plateau that was on average 7.8-fold greater than the initial current ([Figure 2---figure supplement 1A--C](#fig2s1){ref-type="fig"}). In contrast, when the pipet solution contained low (0.6 μM) \[Ca^2+^\]~i~, the currents remained stable after patch break ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}).

Clinical phenotypes of two ARB patients with distinct *BEST1* mutations {#s2-2}
-----------------------------------------------------------------------

Unlike the other bestrophinopathies caused by autosomal dominant mutations in *BEST1*, ARB is associated with recessive mutations. Patients with ARB are characterized by progressive generalized rod-cone degenerations, typically with a visual acuity reading around 20/40 in the first decade of life, and their vision progressively worsens over time ([@bib5]; [@bib18]). In this study, we focused on two diagnosed ARB patients from independent families. Both patients exhibit typical ARB phenotypes in fundus autofluorescence imaging, spectral domain optical coherence tomography (SDOCT) and full-field electroretinography (ERG) ([Figure 3A--C](#fig3){ref-type="fig"}). Unlike EOG which mainly represents the electrical responses of RPE ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), ERG measures the overall activity of various cell types in the retina.

![Clinical phenotypes of two patients with *BEST1* mutations.\
(**A**) Color fundus photographs from patient 1 (P274R) and patient 2 (I201T), right and left eyes, respectively. Both of the patients' fundus show bilateral, confluent curvilinear subretinal yellowish vitelliform deposits (red arrow) superior to the optic disks and encircling the maculae. (**B**) SDOCTs of the macula in patient 1 and patient 2. Scale bar, 200 μm. In Patient 1, there are bilateral, multifocal serous retinal detachments involving the maculae and cystoid deposits in the macula (red arrow). Patient 2 presents a relative preservation of the retina change compared to patient 1. (**C**) ERGs of patient 1 and patient 2 (red lines), right and left eyes, respectively, show extinguished maximum response amplitudes between a- and b-waves, compared to those from age matched *BEST1* WT controls (black lines). See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.](elife-29914-fig3){#fig3}

Patient 1, a 12-year-old otherwise healthy boy, who has a previously described homozygous c.821C \> G; p.P274R mutation in *BEST1* ([@bib12]; [@bib22]), showed reduced visual acuities at 20/60 and 20/70 in the right and left eye, respectively. Color fundus showed bilateral, confluent curvilinear subretinal yellowish vitelliform deposits to the optic disks, which over 3 years of follow-up became more multifocal and dispersed to involve the nasal retinae ([Figure 3A](#fig3){ref-type="fig"}, *left*). SDOCT discovered bilateral, multifocal serous retinal detachments involving the maculae and cystoid changes in the macula ([Figure 3B](#fig3){ref-type="fig"}, *left*). Maximum response of ERG b-wave (amplitudes between a- and b-wave) were 132.6 μV and 194.4 μV in the right and left eye, respectively, contrasting 355 μV (median value) in healthy teenagers tested in the same device ([Figure 3C](#fig3){ref-type="fig"}, *left*).

Patient 2, a 72-year-old otherwise healthy man, who has a homozygous c.602T \> C; p.I201T mutation in *BEST1*, showed a dropped vision acuity at 20/40 in the right eye, and 20/200 in the left eye mainly due to aging-caused retinal atrophy. His color fundus presented less vitelliform deposits compared with patient 1, and aging-caused dispersed punctate fleck lesions in the left eye ([Figure 3A](#fig3){ref-type="fig"}, *right*). SDOCT showed milder cystic degeneration compared to that in Patient 1 ([Figure 3B](#fig3){ref-type="fig"}, *right*). Maximum responses of ERG b-waves were 103.2 μV and 79.6 μV in the right and left eye, respectively, contrasting 287 μV (median value) in age-matched healthy people ([Figure 3C](#fig3){ref-type="fig"}, *right*).

In summary, even though ARB has progressed for 60 years longer, patient 2 has better vision acuity (in his more relevant right eye), less vitelliform deposit, milder cystic degeneration, and better responses to visual stimuli, suggesting that the I201T mutation is less severe than the P274R mutation.

Physiological impact of *BEST1* disease-causing mutations {#s2-3}
---------------------------------------------------------

If the recorded Ca^2+^-dependent Cl^-^ current is responsible for LP, it is logically speculated to be impaired in *BEST1* patient iPSC-RPEs, because reduced LP is a clinical feature in *BEST1* patients. To directly examine the physiological impact of *BEST1* mutations on Ca^2+^-dependent Cl^-^ current in RPE, iPSCs were derived from the patients' skin cells and then differentiated to iPSC-RPEs. RPE-specific marker proteins RPE65 (retinal pigment epithelium-specific 65 kDa protein) and CRALBP (cellular retinaldehyde-binding protein) displayed similar expression levels in the *BEST1* WT and two patient-derived iPSC-RPEs by western blot ([Figure 4A](#fig4){ref-type="fig"}), confirming the mature status of iPSC-RPEs.

![Subcellular localization of BEST1 and surface Ca^2+^-dependent Cl^-^ current in patient-derived iPSC-RPEs.\
(**A**) Western blots show similar BEST1 expression levels in WT and patient-derived iPSC-RPEs. Each sample was from one cell lysis (BEST1 and β-actin, RPE65 and CRALBP were on two gels, respectively). (**B**) Confocal images showing diminished plasma membrane localizations of BEST1 P274R, and normal plasma membrane localization of BEST1 I201T. Scale bar,15 μm. (**C**) Representative current traces recorded from patient iPSC-RPEs at 1.2 μM \[Ca^2+^\]~i~. Scale bar, 500 pA, 150 ms. (**D**) Population steady-state current-voltage relationships in BEST1 WT (●), P274R (▲) and I201T (▼) iPSC-RPEs at 1.2 μM \[Ca^2+^\]~i~; n = 5--6 for each point. ^∗^*p*\<0.05 (2 × 10^−7^ for P274R and 6 × 10^−4^ for I201T) compared to WT using two-tailed unpaired Student *t* test. *Insert*, confocal images showing P274R iPSC-RPE in bright field. Scale bar,10 μm. (**E**) CaCC currents in BEST1 P274R patient iPSC-RPE were rescued by complementation with WT BEST1-GFP. Complementation (▲, n = 5--6 for each point), compared to BEST1 P274R (▲, n = 3--5 for each point), and WT (●). The plots were fitted to the Hill equation. *Insert*, confocal images showing P274R iPSC-RPE complemented with WT BEST1-GFP expressed from a BacMam baculoviral vector. Scale bar,10 μm. (**F**) Ca^2+^-dependent currents in BEST1 I201T iPSC-RPE (▼) compared to WT iPSC-RPE (●). Steady-state current density recorded at +100 mV plotted vs. free \[Ca^2+^\]~i~; n = 5--6 for each point. The plots were fitted to the Hill equation. See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.](elife-29914-fig4){#fig4}

Patient iPSC-RPE carrying the BEST1 P274R mutation showed a similar overall BEST1 expression level compared to that in WT iPSC-RPE ([Figure 4A](#fig4){ref-type="fig"}) in western blot, but exhibited diminished BEST1 antibody staining on the plasma membrane ([Figure 4B](#fig4){ref-type="fig"}, *top*), indicating that the subcellular localization of the channel was severely impaired by the P274R mutation. Strikingly, tiny currents (\< 6 pA/pF) were detected in P274R patient iPSC-RPE at all tested \[Ca^2+^\]~i~ by whole-cell patch clamp ([Figure 4C](#fig4){ref-type="fig"}-E p, and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}), indicating that the P274R mutation abolishes Ca^2+^-dependent Cl^-^ current in RPE. Furthermore, both the membrane localization of BEST1 and the Ca^2+^-dependent Cl^-^ current were rescued in P274R patient iPSC-RPE by complementation with WT BEST1-GFP expressed from a BacMam baculoviral vector ([Figure 4E](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 1A,B,C](#fig4s1){ref-type="fig"}). These results demonstrated that functional BEST1 is necessary for generating Ca^2+^-dependent Cl^-^ current in human RPE.

On the other hand, patient iPSC-RPE carrying the BEST1 I201T mutation showed a similar overall BEST1 level compared to that in WT iPSC-RPE ([Figure 4A](#fig4){ref-type="fig"}), and normal BEST1 antibody staining on the plasma membrane ([Figure 4B](#fig4){ref-type="fig"}, *bottom*). However, I201T patient iPSC-RPE displayed robust but significantly decreased Ca^2+^-dependent Cl^-^ currents compared to those in WT iPSC-RPE ([Figure 4C,D,F](#fig4){ref-type="fig"}, and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Notably, when current amplitudes were normalized, the pattern of Ca^2+^ response was similar in WT and I201T iPSC-RPEs (EC~50~ 455 nM vs. 526 nM, [Figure 4F](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}), indicating that the Ca^2+^ sensitivity of surface Cl^-^ current in RPE is not altered by the I201T mutation.

Taken together, our results showed that the P274R mutation leads to a 'null' phenotype of Ca^2+^-dependent Cl^-^ current in RPE associated with a loss of BEST1 plasma membrane enrichment, while the seemingly milder I201T mutation causes reduced Cl^-^ current in RPE without altering Ca^2+^ sensitivity of the current or subcellular localization of BEST1. Importantly, the P274R patient exhibits a more severe retinal phenotype compared to the I201T patient, suggesting a strong correlation between the status of BEST1, the functionality of RPE surface Ca^2+^-dependent Cl^-^ current, and retinal physiology.

As BEST1 is a CaCC located on the plasma membrane of RPE, the next important question is whether the defective Ca^2+^-dependent Cl^-^ current in *BEST1* patient iPSC-RPEs truly reflects deficiency of the BEST1 channel activity. To directly examine the influence of the disease-causing mutations on BEST1, WT and mutant BEST1 channels were individually introduced into HEK293 cells, which do not have any endogenous CaCC on the plasma membrane ([Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). Western blot confirmed that both WT and the mutant channels were expressed at similar levels after transient transfection ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). As previously reported, HEK293 cells expressing WT BEST1 displayed robust Ca^2+^-dependent currents markedly inhibited by NFA ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), indicating that they were Ca^2+^-dependent Cl^-^ currents ([@bib17]). Consistent with the results in iPSC-RPE, HEK293 cells expressing the P274R mutant yielded no current, while cells expressing the I201T mutant displayed significantly smaller current amplitude compared to that of WT at 1.2 μM \[Ca^2+^\]~i~, where HEK293 cells expressing WT BEST1 conduct peak current amplitude ([Figure 5A,B](#fig5){ref-type="fig"}) ([@bib17]). As HEK293 cells represent a 'blank' background, the recorded Ca^2+^-dependent Cl^-^ currents are genuinely generated from transiently transfected BEST1 channels. Therefore, the two disease-causing mutations lead to distinct defects of the BEST1 channel activity that match the defects of Ca^2+^-dependent Cl^-^ current in iPSC-RPEs, strongly suggesting that BEST1 is the bona fide CaCC on the plasma membrane of RPE mediating Ca^2+^-dependent Cl^-^ current for LP.

![Surface Ca^2+^-dependent Cl^-^ current in HEK293 cells expressing WT and mutant BEST1.\
(**A**) Representative current traces recorded from transfected HEK293 cells at 1.2 μM \[Ca^2+^\]~i~. Scale bar, 150 pA, 150 ms. (**B**) Population steady-state current-voltage relationships for BEST1 WT (●), P274R (▲) and I201T (▼) at 1.2 μM \[Ca^2+^\]~i~; n = 5--6 for each point. ^∗\#^*p*\<0.05 compared to WT (8 × 10^−4^ for P274R and 0.01 for I201T) or to I201T (0.04), respectively, using one-way ANOVA and Bonferroni *post hoc* analyses. See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.](elife-29914-fig5){#fig5}

Disease-causing mechanisms of *BEST1* mutations {#s2-4}
-----------------------------------------------

As an ion channel, how could BEST1 go wrong with the disease-causing mutations? Multiple mechanisms may exist, including massive disruption of the channel structure, alterations in single channel activity, and dysregulation of the channel (e.g. expression). We sought to find critical clues from the channel structure to answer this question.

Since the structure of BEST1 has not been solved, we generated a three-dimensional human homology model based on our previously solved *Klebsiella pneumoniae* bestrophin (KpBest) structure and a chicken bestrophin1 (cBest1) structure ([@bib20]; [@bib36]; [@bib53]) ([Figure 6A](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}, and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). In this BEST1 model, P274 locates at the N-terminal of helix S4a ([Figure 6A,B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}, and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). The presence of Pro in alpha helices normally promotes thermostability of the membrane protein ([@bib40]). The restricted torsion angle for the N--Cα bond of Pro allows only a limited number of conformations and imposes stress on secondary structures in proteins. Substitution of Pro with Arg will release the restrictions and induce instability of local structure, predicting a dramatic disruption of the channel. It should be noted that a Pro to Arg mutation based on the structure model would result in a steric clash between this amino acid and helix S3b, thereby highlighting the major contribution of Pro in the structure ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}).

![Patient mutations in a BEST1 homology model.\
(**A**) *Left*, ribbon diagram of the BEST1 pentamer with each protomer colored differently, as viewed from the side. *Right*, ribbon diagram of two oppositely facing (144°) protomers of a BEST1 pentamer are shown with the extracellular side on the top. The side chains of critical residues are in red. (**B**) Location of the patient mutations in relationship to the channel pore. *Left*, as viewed from the side; *right*, from inside the plasma membrane. (**C**) Visualization of the location of I201T. The side chains of critical residues are in red. See also [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}.](elife-29914-fig6){#fig6}

On the other hand, I201 resides in a loop between S2h and S3a ([Figure 6A,B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}, and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), surrounded by hydrophobic residues V114, A195, L207, and L210 ([Figure 6C](#fig6){ref-type="fig"}), which are conserved among species and thus probably important for the channel function ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). As the Ile to Thr substitution changes a hydrophobic residue to a polar residue, which weakens the hydrophobic interactions, this mutation may change the channel property by altering the local interplays between spatially adjacent subunits, but will unlikely disrupt the channel structure as its localization on a loop renders flexibility. Importantly, the potential influence of the I201T mutation on the channel function is underlined by its proximity to I205 ([Figure 6A,C](#fig6){ref-type="fig"}), a putative activation/permeation gate and the narrowest exit along the ion conducting pathway ([Figure 6A,B](#fig6){ref-type="fig"}) ([@bib53]).

Sequence alignment reveals that BEST1 P274 is identical while I201 has a highly conservative substitution in KpBest (P239 and L177, respectively, [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}, and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), prompting us to test the predictions from the BEST1 homology model with the corresponding KpBest mutants (P239R and L177T, respectively) expressed from *E. coli*. During protein purification, we noticed that the yield of pentameric KpBest P239R was significantly less compared to that of KpBest WT or L177T ([Figure 7A](#fig7){ref-type="fig"}), consistent with the prediction that P274R causes massive disruption, and thus instability, to the channel structure. Purified KpBest mutant proteins were set for crystal growing. While no crystal was grown with KpBest P239R, well-diffracted KpBest L177T crystals were obtained under the same condition as KpBest WT ([@bib53]), and the structure was solved to 3.1 Å resolution ([Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"}). The KpBest L177T structure mirrors that of KpBest WT, with all-atom alignment RMSD (root-mean-square deviation) in a protomer 0.4 Å (Coot LSQ superpose). However, superposition of KpBest WT with the L177T mutant based on the alignment of single chain residues 174--180 showed an obvious shift of the TM region ([Figure 8](#fig8){ref-type="fig"}, and [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). These results strongly support our structural predictions on the BEST1 P274R and I201T mutations.

![Influence of patient mutations on single channel conductance.\
(**A**) Bar chart showing purified KpBest WT and mutant pentameric protein per wet cell yields. n = 3 for each bar. ^∗^*p*\<0.05 compared to WT (2 × 10^−3^) or L177T (0.03) using two-tailed unpaired Student *t* test. (**B**) Current trace of KpBest WT and mutant single channels recorded from planar lipid bilayers at 80 mV with 150 mM NaCl in both cis and trans solutions. Scale bar, 2.5 pA, 250 ms. (**C**) Histograms showing single channel current amplitudes of KpBest WT and the L177T mutant. n = 3.](elife-29914-fig7){#fig7}

![Superposition of KpBest WT with L177T mutant based on regional alignment of residues 174--180.\
Ribbon diagram of the KpBest WT chain A (blue) and KpBest L177T chain A (green) with highlighted stick diagram of residue 177. See also [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"} and [Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.29914.020Figure 8---source data 1.Data collection and refinement statistics of KpBest L177T.^a^Statistics for the highest-resolution shell are shown in parentheses.](elife-29914-fig8){#fig8}

We next assessed the influence of the disease-causing mutations on BEST1 single channel activity. To circumvent the unavailability of purified human BEST1, we utilized the corresponding KpBest P239R and L177T mutants. As previously described ([@bib53]), purified KpBest channels were fused into planar lipid bilayer with 150 mM NaCl in both the *trans* (internal) and *cis* (external) solutions, and single channel currents were recorded with KpBest WT at 80 mV with mean amplitude of 5.5 pA ([Figure 7B](#fig7){ref-type="fig"}). By contrast, no currents were obtained with KpBest P239R, while currents with reduced unitary conductance (mean amplitude 1.5 pA) were recorded with KpBest L177T ([Figure 7B,C](#fig7){ref-type="fig"}), suggesting that the BEST1 P274R and I201T mutations result in a complete and partial loss of single channel activity, respectively. Taken together, we concluded that P274R is a null mutation that abolishes both plasma membrane localization and channel activity of BEST1 due to structural disruption, whereas I201T is a partial loss-of-function mutation that retains plasma membrane localization and Ca^2+^ sensitivity of BEST1 caused by minor structural alterations.

Discussion {#s3}
==========

Here, we first proved the existence of Ca^2+^-dependent Cl^-^ currents on the plasma membrane of human RPE by whole-cell patch clamp. Then we comprehensively examined two *BEST1* disease-causing mutations (P274R and I201T) derived from ARB patients in an interdisciplinary platform, including whole-cell patch clamp with patient-derived iPSC-RPEs and HEK293 cells, immunodetection of endogenous BEST1 in iPSC-RPEs, lipid bilayer with purified bacterial bestrophin proteins, and structural analyses with human models and bacterial homolog crystal structures ([Table 1](#table1){ref-type="table"}). Collectively, our results illustrated the physiological influence of these two mutations on RPE surface Ca^2+^-dependent Cl^-^ current and the BEST1 channel function, and provided structural insights into their disease-causing mechanisms: the P274R mutation abolishes Ca^2+^-dependent Cl^-^ current in vivo, likely due to disruption of the BEST1 channel structure; while the I201T mutation partially impairs Ca^2+^-dependent Cl^-^ current in vivo, likely due to non-disruptive structural alteration ([Table 1](#table1){ref-type="table"}).

10.7554/eLife.29914.021

###### Summary of disease-causing mechanisms of BEST1 P274R and I201T mutations.

                          Mechanism          System                         P274R       I201T              
  ----------------------- ------------------ ------------------------------ ----------- ------------------ -------
  Phenotype               \-                 Patient                        Severe      Mild               
  Function                *I*                CaC current                    RPE         Null               Small
  Ca^2+^ sensitivity      RPE                N/A                            Normal                         
  CaC current of BEST1    HEK293             Null                           Small                          
  *N*                     BEST1 expression   RPE                            Normal      Normal             
  Membrane localization   RPE                Diminished                     Normal                         
  *i*                     Unitary current    KpBest                         Null        Small              
  Structure               \-                 KpBest crystal + human model   Disrupted   Slightly altered   

*I* = *N* × *P*~o~× *i. I*, whole-cell current amplitude; *N*, number of surface channels; *P*~o~, channel open probability; *i*, unitary current.

The structure of BEST1 has not been solved, and only two bestrophin homolog structures- KpBest and cBest1, were reported in previous studies ([@bib20]; [@bib53]). We used both KpBest crystal structures and human homology models mainly based on cBest1 to analyze the possible structural alterations in BEST1 caused by the patient-specific mutations. Results from the two methods are consistent with each other and with functional data. Moreover, it has been proposed that disease mutations may result in wrongly numbered oligomers rather than the correct pentamer formed by WT BEST1 ([@bib18]). The structure of KpBest I177T suggests that the BEST1 I201T mutation does not alter the pentameric conformation of the channel.

Although decreased LP in *BEST1* patients has been attributed to aberrant RPE surface Ca^2+^-dependent Cl^-^ current, how *BEST1* disease-causing mutations physiologically influence Ca^2+^-dependent Cl^-^ current in RPE has not been directly examined. Most previous studies investigated the anion channel function of BEST1 in transiently transfected cell lines ([@bib17]; [@bib18]), while the only two studies done in human RPE by other groups did not directly examine Ca^2+^-dependent Cl^-^ current: one measured transepithelial potential in fhRPE expressing exogenous BEST1 on virus ([@bib31]), and the other investigated volume-dependent current ([@bib35]). We recently used anion sensitive fluorescent dyes to compare Ca^2+^-stimulated Cl^-^ secretion in *BEST1* WT and mutant donor iPSC-RPEs, but neither the surface Cl^-^ current nor Ca^2+^ sensitivity was directly measured ([@bib36]). Here we clearly demonstrated with whole-cell patch clamp that the surface Ca^2+^-dependent Cl^-^ current in patient-derived iPSC-RPEs is completely abolished and significantly reduced by the P274R and I201T mutations, respectively, providing the first direct evidence that *BEST1* disease-causing mutations impair Ca^2+^-dependent Cl^-^ current in human RPE. Our results strongly argue that BEST1 is the CaCC mediating Ca^2+^-dependent Cl^-^ current in human RPE, because: 1) the surface Ca^2+^-dependent Cl^-^ current is completely defective in iPSC-RPE with the P274R mutation, which generates an essentially 'null' BEST1 channel with loss of plasma membrane enrichment in RPE and no ion conductivity in HEK293 cells and bilayer (KpBest P239R), suggesting that BEST1 is indispensable for Ca^2+^-dependent Cl^-^ current in RPE; 2) the I201T mutation results in significantly reduced conductivity of the channel in both HEK293 cells and bilayer (KpBest L177T), and concomitantly leads to much smaller Ca^2+^-dependent Cl^-^ currents in the patient iPSC-RPE, in which the mutant BEST1 channels are still expressed and enriched on the plasma membrane, suggesting that the CaCC function of membrane located BEST1 orchestrates Ca^2+^-dependent Cl^-^ current in RPE; 3) the I201T mutation does not affect the Ca^2+^ sensitivity of Cl^-^ current in RPE, consistent with the non-involvement of I201 in Ca^2+^ binding according to the cBest1 crystal structure model ([@bib20]). The simplest and most logical conclusion based on our results is that BEST1 functions as the surface CaCC to generate Ca^2+^-dependent Cl^-^ current in human RPE.

A recent report with primary mouse RPE and the human RPE-derived ARPE-19 cell line suggested that TMEM16B is the CaCC responsible for Ca^2+^-stimulated Cl^-^ current in those cells ([@bib21]), while a role of TMEM16A was proposed by another study using Cl^-^ channel blockers in porcine RPE ([@bib42]). It should be noted that *Best1* knockout mice do not have any retinal abnormality or aberrant Cl^-^ current ([@bib29]; [@bib35]), unlike the phenotypes seen with human *BEST1* mutations, suggesting different genetic requirements for retinal physiology among species. Moreover, the expression of BEST1 in the ARPE-19 cell line may be different from that in iPSC-RPE and fhRPE ([@bib28]). In any case, our results do not completely exclude the role of other CaCCs in contributing to Ca^2+^-dependent Cl^-^ current in human RPE.

Besides its CaCC function on the basolateral plasma membrane of RPE, other roles of BEST1 have also been suggested including HCO~3~^-^ channel, volume-regulated Cl^-^ channel, regulator of Ca^2+^ channels, and Ca^2+^ sensor on the endoplasmic reticulum membrane ([@bib3]; [@bib5]; [@bib9]; [@bib16]; [@bib39]; [@bib41]; [@bib55]). Here we focused on the CaCC function of BEST1 in conducting surface Ca^2+^-dependent Cl^-^ current, which directly gives rise to LP, but did not exclude any indirect contribution of BEST1 to LP through its non-CaCC function(s). For instance, BEST1 may affect a downstream CaCC (e.g. TMEM16A or TMEM16B) through regulating intracellular Ca^2+^.

Interestingly, we found remarkable differences in the Ca^2+^ sensitivity of Cl^-^ current in different cell types. The lower Ca^2+^ sensitivities in fhRPE (EC~50~ 1.7 μM) compared to that in *BEST1* WT iPSC-RPE (EC~50~ 455 nM) may result from the cells' different developmental stages, considering that fetuses do not have a fully functional visual system and therefore probably only need less sensitive CaCCs in their RPEs. The higher Ca^2+^ sensitivity of heterologously expressed BEST1 in HEK293 cells (EC~50~ \~150 nM) has been reported in previous studies ([@bib25]; [@bib49]), while purified cBest1 displays an even smaller EC~50~ of 17 nM in bilayer ([@bib48]). Considering the role of BEST1 as the CaCC in RPE, the significant difference of Ca^2+^ sensitivities may reflect intrinsic differences between RPE where BEST1 is endogenously expressed and other experimental systems with overexpressed or purified proteins. It is also possible that in native RPE, BEST1 senses Ca^2+^ not only through direct interaction as suggested by the cBest1 model ([@bib20]), but also indirectly via a third-party Ca^2+^-sensor protein or by posttranslational modification mechanisms (e.g. phosphorylation) ([@bib17]), to function properly under the sophisticated physiological environment. Notably, the Ca^2+^ sensitivity observed in *BEST1* WT iPSC-RPE (EC~50~ 455 nM) is at levels more comparable to physiological conditions than that detected in HEK293 cells over-expressing BEST1 (EC~50~ \~150 nM), let alone cBest1 in bilayer (EC~50~ 17 nM), because basal \[Ca^2+^\]~i~ in the human body is typically around 100 nM, meaning that CaCCs with a EC~50~ near or lower than 100 nM would be readily activated even in resting cells.

In regard to the clinical treatment of bestrophinopathies, our study provided an important proof-of-concept for treating ARB caused by *BEST1* recessive mutations, as the loss of Ca^2+^-dependent Cl^-^ current in the 'null' BEST1 P274R iPSC-RPE was rescued by viral expression of WT BEST1. It will be very intriguing to see if ARB patients can be treated by gene therapy delivering functional WT BEST1 to their RPEs. Notably, most of the *BEST1* patient-specific mutations are dominant, so that the mutant *BEST1* alleles in these cases may be more functionally defective and/or structurally disruptive compared to recessive mutant alleles in ARB patients. Although it is formally possible that overexpression of WT BEST1 can also rescue, in a dominant-negative matter, aberrant Ca^2+^-dependent Cl^-^ current in RPE caused by *BEST1* dominant mutations, further studies will be needed to test this premise.

On the other hand, recessive *BEST1* mutations from ARB patients provide a unique opportunity to analyze and connect the structure, function and physiological role of BEST1 in a 'clean' manner, as only the mutant BEST1 proteins are present in patients and all our experimental systems. By contrast, the co-existence of both WT and mutant BEST1 proteins in the cases of dominant mutations complicates the functional-structural analyses for several reasons: (1) as the pentameric bestrophin channels consist of five protomers, different numbers (0--5) of BEST1 mutant protomers could potentially be assembled to a BEST1 pentamer and impact the channel structure and function; (2) although the ratio of endogenous WT to mutant BEST1 proteins is key to determine the composition of pentameric BEST1 channels in patients, this critical factor cannot be determined by either western blot or immunostaining, as the BEST1-specific antibody cannot distinguish WT and mutant BEST1 proteins; (3) crystallographic studies with the BEST1 dominant mutant proteins only reflect homopentamers consisting of all five mutant protomers, but not heteropentamers with 1--4 mutant protomers; (4) it could be technically challenging to rescue phenotypes caused by dominant mutations, and thus hard to draw a clear conclusion. Nevertheless, we are actively investigating *BEST1* dominant mutations using the pipelines established in this work with necessary modifications and cautions.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\     Designation                      Source or reference                                        Identifiers                                                      Additional information
  or resource                                                                                                                                                                              
  --------------------------- -------------------------------- ---------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------
  gene (human)                BEST1                            PMID: 25324390                                                                                                              

  gene\                       KpBest                           PMID: 25324390                                                                                                              
  (*Klebsiella pneumoniae*)                                                                                                                                                                

  strain, strain\             DH5alpha                         other                                                                                                                       Laboratory of\
  background (*E.coli*)                                                                                                                                                                    Wayne Hendrickson

  strain, strain\             BL21 plysS                       other                                                                                                                       Laboratory of\
  background (*E. coli*)                                                                                                                                                                   Wayne Hendrickson

  cell line (human)           HEK293                           other                                                      RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)       Laboratory of\
                                                                                                                                                                                           David Yule

  transfected\                pEGFP-N1-BEST1 WT                PMID: 25324390                                                                                                              
  construct (human)                                                                                                                                                                        

  transfected\                pEGFP-N1-BEST1 I201T             this paper                                                                                                                  Made from\
  construct (human)                                                                                                                                                                        pEGFP-N1-BEST1\
                                                                                                                                                                                           WT by site-directed mutagenesis

  transfected\                pEGFP-N1-BEST1 P274R             this paper                                                                                                                  Made from\
  construct (human)                                                                                                                                                                        pEGFP-N1-BEST1 WT by\
                                                                                                                                                                                           site-directed mutagenesis

  biological\                 skin cells                       other                                                                                                                       New York\
  sample (human)                                                                                                                                                                           Presbyterian Hospital

  biological\                 fetus eye samples                other                                                                                                                       New York\
  sample (human)                                                                                                                                                                           Presbyterian Hospital

  biological\                 BEST1 WT iPSC-RPE                this paper                                                                                                                  Generated from\
  sample (human)                                                                                                                                                                           donor skin cells by\
                                                                                                                                                                                           re-programming and\
                                                                                                                                                                                           differentiation

  biological\                 BEST1 I201T iPSC-RPE             this paper                                                                                                                  Generated from\
  sample (human)                                                                                                                                                                           donor skin cells by\
                                                                                                                                                                                           re-programming and\
                                                                                                                                                                                           differentiation

  biological\                 BEST1 P274R iPSC-RPE             this paper                                                                                                                  Generated from\
  sample (human)                                                                                                                                                                           donor skin cells by\
                                                                                                                                                                                           re-programming and\
                                                                                                                                                                                           differentiation

  antibody                    BESTROPHIN1                      Novus Biologicals NB300-164                                RRID:[AB_10003019](https://scicrunch.org/resolver/AB_10003019)   1:200

  antibody                    ZO-1                             Invitrogen 40--2200                                        RRID:[AB_2533456](https://scicrunch.org/resolver/AB_2533456)     1:500

  antibody                    Alexa Fluor 488-conjugated IgG   Invitrogen A-11070                                         RRID:[AB_2534114](https://scicrunch.org/resolver/AB_2534114)     1:1000

  antibody                    Alexa Fluor 555-conjugated IgG   Invitrogen A-21422                                         RRID:[AB_2535844](https://scicrunch.org/resolver/AB_2535844)     1:1000

  antibody                    RPE65                            Novus Biologicals NB100-355                                RRID:[AB_10002148](https://scicrunch.org/resolver/AB_10002148)   1:1000

  antibody                    CRALBP                           Abcam ab15051                                              RRID:[AB_2269474](https://scicrunch.org/resolver/AB_2269474)     1:500

  antibody                    β-actin                          Abcam ab8227                                               RRID:[AB_2305186](https://scicrunch.org/resolver/AB_2305186)     1:2000

  antibody                    GFP                              Invitrogen A6455                                           RRID:[AB_221570](https://scicrunch.org/resolver/AB_221570)       1:5000

  antibody                    SOX2, Tra-1--60, SSEA4, Nanog    Abcam ab109884                                                                                                              1:200

  antibody                    EEA1                             Fisher Scientific MA5-14794                                RRID:[AB_10985824](https://scicrunch.org/resolver/AB_10985824)   1:200

  recombinant\                pEG Bacmam                       other                                                                                                                       Laboratory of Eric Gouaux
  DNA reagent                                                                                                                                                                              

  recombinant\                pEG Bacmam-BEST1-GFP             this paper                                                                                                                  Made from\
  DNA reagent                                                                                                                                                                              pEG Bacmam by\
                                                                                                                                                                                           inserting BEST1-GFP

  recombinant\                BEST1-GFP Bacmam virus           this paper                                                                                                                  Produced from\
  DNA reagent                                                                                                                                                                              pEG Bacmam-BEST1-GFP\
                                                                                                                                                                                           by published protocols\
                                                                                                                                                                                           ([@bib15])

  recombinant\                pMCSG7-10xHis-KpBest^ΔC11^       PMID: 25324390                                                                                                              
  DNA reagent                                                                                                                                                                              

  recombinant\                pMCSG7-10xHis-KpBest^ΔC11^\      this paper                                                                                                                  Made from\
  DNA reagent                 L177T                                                                                                                                                        pMCSG7-\
                                                                                                                                                                                           10xHis-KpBest^ΔC11^\
                                                                                                                                                                                           by site-directed\
                                                                                                                                                                                           mutagenesis

  recombinant\                pMCSG7-10xHis-KpBest^ΔC11^\      this paper                                                                                                                  Made from\
  DNA reagent                 P239R                                                                                                                                                        pMCSG7-\
                                                                                                                                                                                           10xHis-KpBest^ΔC11^\
                                                                                                                                                                                           by site-directed\
                                                                                                                                                                                           mutagenesis

  sequence-based\             BEST1 I201T forward primer       this paper                                                                                                                  ACCCGGGACC\
  reagent                                                                                                                                                                                  CTATCCTGCT

  sequence-based\             BEST1 I201T reverse primer       this paper                                                                                                                  GATAGGGTCCCGGG\
  reagent                                                                                                                                                                                  TTCGACCTCCAAGCCACG

  sequence-based\             BEST1 P274R forward primer       this paper                                                                                                                  CGCGTCTTCAC\
  reagent                                                                                                                                                                                  GTTCCTGCAGTT

  sequence-based\             BEST1 P274R reverse primer       this paper                                                                                                                  GAACGTGAAGAC\
  reagent                                                                                                                                                                                  GCGCACAACGAGGT

  sequence-based\             KpBest L177T forward primer      this paper                                                                                                                  ACCAGCGACA\
  reagent                                                                                                                                                                                  TCACTTACGGGC

  sequence-based\             KpBest L177T reverse primer      this paper                                                                                                                  AGTGATGTCGCT\
  reagent                                                                                                                                                                                  GGTCTTGCCCGCCTCCCG

  sequence-based\             KpBest P239R forward primer      this paper                                                                                                                  CGGTTTGTCTCGGTC\
  reagent                                                                                                                                                                                  TTTATCTCTTACACC

  sequence-based\             KpBest P239R reverse primer      this paper                                                                                                                  GACCGAGAC\
  reagent                                                                                                                                                                                  AAACCGCGTCA\
                                                                                                                                                                                           TGTA GTGCAGATCGC

  peptide,\                   KpBest^ΔC11^ L177T               this paper                                                                                                                  Expressed from\
  recombinant protein                                                                                                                                                                      E. coli BL21 plysS,\
                                                                                                                                                                                           and purified by\
                                                                                                                                                                                           affinity and\
                                                                                                                                                                                           size-exclusion\
                                                                                                                                                                                           chromatography

  peptide,\                   KpBest^ΔC11^ P239R               this paper                                                                                                                  Expressed from\
  recombinant protein                                                                                                                                                                      E. coli BL21\
                                                                                                                                                                                           plysS, and purified\
                                                                                                                                                                                           by affinity and\
                                                                                                                                                                                           size-exclusion\
                                                                                                                                                                                           chromatography

  commercial\                 CytoTune-iPS 2.0\                Thermo Fisher Scientific A16517                                                                                             
  assay or kit                Sendai Reprogramming Kit                                                                                                                                     

  commercial\                 In-fusion Cloning Kit            Clontech 639645                                                                                                             
  assay or kit                                                                                                                                                                             

  chemical compound,\         mTeSR-1 medium                   STEMCELL Technologies 5850                                                                                                  
  drug                                                                                                                                                                                     

  chemical compound,\         matrigel                         CORNING 356230                                                                                                              
  drug                                                                                                                                                                                     

  chemical compound,\         nicotinamide                     Sigma-Aldrich N0636                                                                                                         
  drug                                                                                                                                                                                     

  chemical compound,\         Activin-A                        PeproTech 120--14                                                                                                           
  drug                                                                                                                                                                                     

  software, algorithm         XDS                              PMID: 20124692                                                                                                              

  software, algorithm         Phaser                           PMID: 19461840                                             RRID:[SCR_014219](https://scicrunch.org/resolver/SCR_014219)     

  software, algorithm         Phenix                           PMID: 20124702                                             RRID:[SCR_014224](https://scicrunch.org/resolver/SCR_014224)     

  software, algorithm         Coot                             PMID: 15572765                                             RRID:[SCR_014222](https://scicrunch.org/resolver/SCR_014222)     

  software, algorithm         PyMOL                            <http://www.pymol.org/>                                    RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)     

  software, algorithm         Origin                           <http://www.originlab.com/index.aspx?go=PRODUCTS/Origin>   RRID:[SCR_014212](https://scicrunch.org/resolver/SCR_014212)     

  software, algorithm         MODELLER                         PMID: 14696385                                             RRID:[SCR_008395](https://scicrunch.org/resolver/SCR_008395)     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Generation of human iPSC {#s4-1}
------------------------

Primary fibroblasts cells from donors were reprogrammed into pluripotent stem cells using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific, A16517), and immunocytofluorescence assays were performed for scoring iPSC pluripotency following the previously published protocol ([@bib26]). In brief, a panel of antibodies (1:200, abcam, ab109884) against four standard pluripotency markers SOX2, Tra-1--60, SSEA4 and Nanog were applied to characterize the iPSCs from all the subjects enrolled in this study. Hoechst staining was applied to detect nuclei. Secondary antibodies were Alexa Fluor 488 conjugated goat anti-rabbit or Alexa Fluor 555 conjugated goat anti-mouse IgG (1:1,000; Life Technologies). Images for all antibody labels were taken under the same settings with fluorescence microscope (NIKON, Eclipse, Ts2R). All iPSC lines were maintained in mTeSR-1 medium (STEMCELL Technologies, 05850) and passaged every 3--6 days. The morphology and nuclear/cytoplasmic ratio of the iPSC lines were closely monitored to ensure the stability. To verify genome integrity, all the iPSC lines in this study were sent for karyotyping by G-banding at the Cell Line Genetics (Wisconsin, USA).

Differentiation of iPSC into RPE {#s4-2}
--------------------------------

iPSC differentiation started at passage 4 for all iPSC lines. For differentiation, iPSC colonies were cultured to confluence in 6-well culture dishes (Costar, Corning, Corning, NY) pretreated with 1:50 diluted matrigel (CORNING, 356230) in differentiation medium consisting of Knock-Out (KO) DMEM (Thermo Fisher Scientific, 10829018), 15% KO serum replacement (Thermo Fisher Scientific, 10829028), 1% nonessential amino acids (Thermo Fisher Scientific, 11140050), 2 mM glutamine (Thermo Fisher Scientific, 35050061), 50 U/ml penicillin-streptomycin (Thermo Fisher Scientific, 10378016), and 10 mM nicotinamide (Sigma-Aldrich, N0636) for the first 14 days. During the 15^th^-28^th^ days of differentiation, 100 ng/ml human Activin-A (PeproTech, 120--14) was supplemented into differentiation medium. From day 29, Activin-A supplementation was stopped until differentiation was completed. After 8--10 weeks, pigmented clusters were formatted and manually picked, then plated on matrigel-coated dishes in RPE culture medium as previous described ([@bib27]). They were cultured for another 6--8 weeks to allow them to form a functional monolayer for function assay. Besides well-established classical mature RPE markers RPE65, Bestrophin1 and CRALBP, two additional RPE markers, MITF and PAX6, were used for RPE fate validation. All the iPSC-RPE cells used in this study were at their passage 1. Mutations (P274R and I201T) in the mutant iPSC-RPEs were verified by sequencing.

Cell lines {#s4-3}
----------

HEK293 cells were gifts from Dr. David Yule at University of Rochester. Although HEK293 is on the list of commonly misidentified cell lines maintained by the International Cell Line Authentication Committee, the HEK293 cells used in this study were authenticated by short tandem repeat (STR) DNA profiling. No mycoplasma contamination was found. Low-passage-number HEK293 cells were maintained in DMEM supplemented with 10% FBS and 100 μg/ml penicillin-streptomycin.

Immunofluorescence {#s4-4}
------------------

Immunofluorescence staining was performed in all iPSC-RPE lines and human fetal RPE cells. Cells were washed with PBS and fixed in 4% paraformaldehyde for 45 min at room temperature. After washing with PBS twice, the cells were incubated in PBS with 0.1% Triton X-100% and 2% donkey serum for 45 min. Then, primary antibodies against BESTROPHIN-1 (1:200, Novus Biologicals, NB300-164), ZO-1 (1:500, Invitrogen Life Technologies, 40--2200) and EEA1 (1:200, Thermo Fisher Scientific, MA5-14794) were applied to each sample for 2 hr at room temperature. Alexa Fluor 488-conjugated and Alexa Fluor 555-conjugated IgG (1:1,000, Thermo Fisher Scientific) were used as secondary antibodies. Hoechst was used to detect the cell nuclei. Stained cells were observed by confocal microscopy (Nikon Ti Eclipse inverted microscope for scanning confocal microscopy, Japan).

Electrophysiology {#s4-5}
-----------------

Whole-cell recordings of RPE and HEK cells were conducted 48--72 hr after splitting the cells or transfection, respectively, using an EPC10 patch clamp amplifier (HEKA Electronics) controlled by Patchmaster software (HEKA). Micropipettes were fashioned from 1.5 mm thin-walled glass with filament (WPI Instruments) and filled with internal solution containing (in mM): 130 CsCl, 1 MgCl~2~, 10 EGTA, 2 MgATP (added fresh), 10 HEPES (pH 7.4), and CaCl~2~ to obtain the desired free Ca^2+^ concentration (maxchelator.stanford.edu/CaMgATPEGTA-TS.htm). Series resistance was typically 1.5--2.5 MΩ. There was no electronic series resistance compensation. External solution contained (in mM): 140 NaCl, 5 KCl, 2 CaCl~2~, 1 MgCl~2~, 15 glucose and 10 HEPES (pH 7.4). Whole-cell I-V curves were generated from a family of step potentials (−100 to +100 mV from a holding potential of 0 mV). Currents were sampled at 25 kHz and filtered at 5 or 10 kHz. Traces were acquired at a repetition interval of 4 s ([@bib52]).

Purified full length KpBest proteins were fused to planar lipid bilayers formed by painting a lipid mixture of phosphatidylethanolamine and phosphatidylcholine (Avanti Polar Lipids) in a 3:1 ratio in decane; across a 200 µm hole in polysulfonate cups (Warner Instruments) separating two chambers. The *trans* chamber (1.0 ml), representing the intra-SR (luminal) compartment, was connected to the head stage input of a bilayer voltage clamp amplifier. The *cis* chamber (1.0 ml), representing the cytoplasmic compartment, was held at virtual ground. Solutions were as follows (in mM): 150 NaCl, and 10 HEPES (pH 7.4) in the *cis* and *trans* solution. Purified proteins were added to the *cis* side and were fused with the lipid bilayer. Single-channel currents were recorded using a Bilayer Clamp BC-525D (Warner Instruments, LLC, CT), filtered at 1 kHz using a Low-Pass Bessel Filter 8 Pole (Warner Instruments, LLC, CT), and digitized at 4 kHz. All experiments were performed at room temperature (23 ± 2°C).

Immunoblot analysis {#s4-6}
-------------------

Total cellular protein was extracted by M-PER mammalian protein extraction reagent buffer (Pierce, 78501) with proteinase inhibitor (Roche Diagnostics), and quantified by Bio-Rad protein reader. Protein samples (20 μg) were then separated on 10% Tris--Cl gradient gel and electro-blotted onto nitrocellulose membrane. The membranes were incubated in blocking buffer for 1 hr at room temperature, washed three times in PBS with 0.1% Tween for 5 min each, and incubated with primary antibody in blocking buffer overnight at 4°C. Primary antibodies against the following proteins were used for western blots: RPE65 (1:1,000 Novus Biologicals, NB100-355), BESTROPHIN-1 (1:500 Novus Biologicals, NB300-164), CRALBP (1:500 Abcam, ab15051), β-actin (1:2,000 Abcam, ab8227), and GFP (1:5,000 Invitrogen, A6455). Mouse and rabbit secondary antibodies were obtained from Santa Cruz and used at a concentration of 1: 5000.

Virus {#s4-7}
-----

WT BEST1-GFP expressed from a BacMam baculoviral vector was made as previously described ([@bib15]), and was added into RPE culture 24 hr after splitting the cells (MOI = 100).

cDNA cloning {#s4-8}
------------

P237R and L177T KpBest^ΔC11^ have 11 residues truncated from the C-terminus of wild-type KpBest. The wild-type BEST1 (synthesized by Genscript), was amplified using polymerase chain reaction (PCR), and was subcloned into a pEGFP-N1 mammalian expression vector. C-terminus truncated KpBest and point mutations of KpBest and BEST1 were made using the In-fusion Cloning Kit (Clontech). All clones were verified by sequencing.

Transfection {#s4-9}
------------

For electrophysiology experiments, HEK293 cells cultured in 6 cm tissue culture dishes were transiently transfected with the indicated BEST1 (6 μg) and T antigen (2 μg), using the calcium phosphate precipitation method. Cells were washed with PBS 4--8 hr after transfection and maintained in supplemented DMEM, and replated onto fibronectin-coated glass coverslips 24 hr after transfection ([@bib51]).

Protein production and purification {#s4-10}
-----------------------------------

BL21 plysS cells were gifts from Dr. Wayne Hendrickson. For scaling up, transformed BL21 plysS cells were grown at 37°C in TB media to OD 0.6--0.8 after being inoculated with 1% of the overnight culture. The culture was induced with 0.4 mM IPTG and continued to grow at 37°C for another 4 hr.

BL21 plysS cells expressing targeted proteins were harvested by centrifugation and stored at −80°C before use. Cells were resuspended in a buffer containing 50 mM HEPES (pH 7.8) and 200 mM NaCl and lysed using a French Press with two passes at 15--20,000 psi. Cell debris was removed by centrifugation at 10,000 g for 20 min, and the membrane fraction was isolated from that supernatant by ultra-centrifugation at 150,000 g for 1 hr.

The membrane fraction was homogenized in a solubilization buffer containing 50 mM HEPES (pH 7.8) and 300 mM NaCl, and incubated with a final concentration of 0.05% (w/v) DDM for 1 hr at 4°C. The non-dissolved matter was removed by ultracentrifugation at 150,000 g for 30 min, and the supernatant was loaded to a 5 ml Hitrap Ni^2+^-NTA affinity column (GE Healthcare), pre-equilibrated with the same solubilization buffer supplemented with 0.05% DDM. After 20 column volume buffer wash, the protein was eluted with 500 mM imidazole in the solubilization buffer. The 10-His tags were removed by adding super TEV at 1:1 mass ratio and incubating at 4°C for 30 min. Tag removal was confirmed by SDS-PAGE, and the resulting sample was concentrated to approximately 10 mg/ml. Preparative size-exclusion chromatography was carried out on a Superdex-200 column for further purification, including removal of TEV protease and the cleaved tag. The gel-filtration buffer contained 40 mM HEPES (pH 7.8), 200 mM NaCl, 0.1 mM Tris \[2-carboxyethyl\] phosphine (TCEP), and 2 × CMC of detergent DDM.

Crystallization and data collection {#s4-11}
-----------------------------------

Purified protein was concentrated to \~10 mg/ml. Crystals were all grown at 20°C using the sitting-drop vapor diffusion method. The condition contained 0.05 M zinc acetate, 6% v/v ethylene glycol, 0.1 M sodium cacodylate, pH 6.0, and 6.6 % w/v PEG 8000. Cryoprotection was achieved by adding 20% ethylene glycol to the crystallization solution. High resolution native data set from a single L177T KpBest^ΔC11^ crystal was collected at APS (Argonne National Laboratory) beamline 24-ID-E.

Statistics {#s4-12}
----------

### Electrophysiological data and statistical analyses {#s4-12-1}

Whole-cell clamp data were analyzed off-line using Patchmaster (HEKA), Microsoft Excel and Origin software. Statistical analyses were performed in Origin using built-in functions. Statistically significant differences between means (*p*\<0.05) were determined using Student's *t* test for comparisons between two groups, and one-way ANOVA and Bonferroni *post hoc* analyses between more than two groups. Data are presented as means ± s.e.m ([@bib50]).

### Structure determination and refinement {#s4-12-2}

The x-ray data set on L177T KpBest^ΔC11^ was processed using XDS ([@bib19]) via the RAPD system of APS NE-CAT. The structure was solved using WT KpBest^ΔC11^ structure (PDB code: 4WD8) as a search model during molecular replacement, carried out using the program Phaser ([@bib33]) as implemented in the program Phenix suite ([@bib1]). Model building and refinement were carried out using the programs Coot ([@bib8]) and Phenix suite ([@bib1]). The statistics for the diffraction data and refinement are summarized in [Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"}.

### Homology modeling of human BEST1 {#s4-12-3}

Homology models for BEST1 were generated using MODELLER ([@bib10]). All figures were made in PyMOL.

### Data and software availability {#s4-12-4}

The data reported in this paper are tabulated in [Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"}, and deposited to the Protein Data Bank with access codes listed in [Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"}.

Study approval {#s4-13}
--------------

### Patients and clinical analysis {#s4-13-1}

Patient 1 is a 12-year-old otherwise healthy boy, and patient 2 is a 72-year-old otherwise healthy man. Two BEST1-mutant patients underwent a complete ophthalmic examination by a retinal physician in the Department of Ophthalmology, Columbia University Medical Center/New York Presbyterian Hospital. This included best-corrected visual acuity, slit-lamp biomicroscopy, and dilated funduscopy. Both of the patients underwent color fundus photography, optical coherence tomography (OCT) and electroretinogram (ERG) ([@bib23]; [@bib34]). Skin biopsy samples were obtained from patients and healthy control donors, and processed and cultured as previously described ([@bib26]). Patients and the parent/legal guardian of patient 1 provided written informed consent for all procedures, which were approved by Columbia University Institutional Review Board (IRB) protocol AAAF1849.

### Fetal human RPE isolation and culture {#s4-13-2}

Human RPE cells were isolated and cultured from human fetal eye samples (13 to 14 weeks old) obtained from Department of OB/GYN, New York Presbyterian Hospital (Protocol number: IRB-AAAO1804 and IRB-AAAQ7782), as described previously ([@bib44]). In brief, the eyeball with anterior portions and vitreous was removed and then incubated in 2% dispase at 37°C for 45 min. Next, the RPE layer was separated from the choroid layer and transferred to a 15 ml conical tube containing 0.25% trypsin-EDTA. Then the tube was incubated in 37°C water bath for 10 min. After centrifugation at 0.8 rpm for 4 min, the cell pellet was resuspended in RPE medium and plated on a matrigel coated petri dish. All the fetal RPE cells used in this study were at their passage 1.
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Human subjects: Two BEST1-mutant patients (12-year-old and 72-year-old, respectively) underwent a complete ophthalmic examination by a retinal physician in the Department of Ophthalmology, Columbia University Medical Center/New York Presbyterian Hospital. This included best-corrected visual acuity, slit-lamp biomicroscopy, and dilated funduscopy. Both of the patients underwent color fundus photography, optical coherence tomography (OCT) and electroretinogram (ERG). Skin biopsy samples were obtained from patients and healthy control donors, and processed and cultured as previously described (Li et al, 2016). Patients and the parent/legal guardian of patient 1 (12-year-old) provided written informed consent for all procedures, which were approved by Columbia University Institutional Review Board (IRB) protocol AAAF1849. Human RPE cells were isolated and cultured from human fetal eye samples (13 to 14 weeks old) obtained from Department of OB/GYN, New York Presbyterian Hospital (Protocol number: IRB-AAAO1804 and IRB-AAAQ7782), as described previously (Sonoda et al, 2009).
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Major datasets {#s7}
--------------

The following dataset was generated:

Zhang YChen SYang T2017Crystal structure of a bacterial Bestropin homolog from Klebsiella pneumoniae with a mutation L177T<http://www.rcsb.org/pdb/explore/explore.do?structureId=5X87>Publicly available at the RCSB PDB website (accession no. 5X87)

The following previously published dataset was used:

Yang TLiu QHendrickson WA2014Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae<http://www.rcsb.org/pdb/explore/explore.do?structureId=4WD8>Publicly available at the RCSB PDB website (accession no: 4WD8)

10.7554/eLife.29914.027
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Patient-specific mutations impair an essential role of BESTROPHIN1\" for consideration by *eLife*. Three experts reviewed your manuscript, and their assessments, together with my own (Reviewing Editor), form the basis of this letter. The evaluation has been overseen by Richard Aldrich as the Senior Editor.

As you will see, all of the reviewers were impressed with the importance and novelty of your work, but they also had a wide variety of critiques. I am including the three reviews at the end of this letter, as there are many specific and useful suggestions in them.

In further discussions among the reviewers, the major questions that arose focused on:

1\) Potential variability among different cell lines from the same donor -- i.e. how reproducible are the data obtained from different cell lines?

2\) The distinction between *Best1* current and other non-*Best1* currents (e.g. VRAC) -- i.e. a fuller characterization of the rescued current.

We appreciate that the reviewers\' comments cover a very broad range of suggestions for improving the manuscript. Please use your best judgment in deciding which of these can be accommodated in a reasonable period of time. We look forward to receiving your revised manuscript.

*Reviewer \#1:*

This study provides the first direct evidence that the endogenous human Bestrophin 1 is responsible for calcium-dependent chloride current in human RPE cells and that disease-associated mutations in human Bestrophin 1 abolishes this current in human RPE cells. This study also offers the most direct evidence that Best disease is a channelopathy caused by a defective calcium-activated chloride channel and overcomes the difficulty of previous mouse models. This achievement warrants its publication in *eLife*. This reviewer does not suggest any further experiments, but suggests improvements in the Discussion and presentation. Here are a few high relevant points that can be discussed to improve the manuscript:

1\) What are the differences in locations between the recessive mutations and dominant mutations in Bestrophin 1? Can the structural model predict or make sense of this functional difference? Since the data showed that the recessive mutants are still expressed at the protein level, it is surprisingly that the mutant subunit does not interfere with the function of the wild-type subunits in the pentamer (it does, it would be a dominant mutant).

2\) The authors write \"in any case, our results do not exclude the role of TMEM16A/TMEM16B in regulating Ca^2+^-dependent Cl^-^ current in human RPE.\" However, the authors presented data showing that RPE cells with the mutant Bestrophin 1 lacks any Ca^2+^-dependent Cl^-^ current. This data does exclude the role of TMEM16A/TMEM16B in regulating Ca^2+^-dependent Cl^-^ current in human RPE.

3\) The authors state \"most of the *BEST1* patient-specific mutations are dominant, so that the mutant *BEST1* alleles in these cases may be gain-of-function as oppose to the loss-of-function alleles in ARB patients.\" There is only evidence to suggest that the dominant mutations are loss-of-function mutations. Is there any evidence that the dominant mutations cause a gain of function? This is also related to discussion point 1 above.

4\) This study\'s demonstration that Bestrophin 1 is responsible for the calcium-dependent chloride current in human RPE cells makes sense physiologically and clinically given the fact that EOG is used routinely as a clinical tool to detect Best disease in human patients. Can the authors explain the difficulty to demonstrate this activity in mouse models and the lessons that can be learned on drawing conclusions using mouse models, which are still the most common used models?

*Reviewer \#2:*

1\) N=1 Patient iPSC-RPE I201T (mild phenotype), N=1 Patient iPSC-RPE P274R (extreme phenotype). These findings should be replicated using more clones per iPSC line. Low N number cannot mitigate donor/clonal variability, which has been seen to be quite high in patient and control iPSC samples.

2\) The authors state: \"Here for the first time, we directly measured Ca^2+^- dependent Cl currents on the plasma membrane of human RPEs by whole-cell patch clamp\" This statement raises a critical question: Where is *Best1* localized \"on the plasma membrane\" in these human RPEs?

• Is it the apical or basolateral membrane? The authors stain for ZO-1 and *Best1*, but ZO-1 is an apical membrane marker. Immunostaining is low resolution, but it shows that *BEST1* does *not* co-localize with ZO1. It seems cytoplasmic. Authors can rule out cytoplasmic localization using ER and Endosome markers. In other systems, basolateral localization is indicated (Johnson et al., 2017). Typical apical membrane markers for human RPE are ezrin or N/K ATPase and collagen IV is a marker for the basolateral membrane.

3\) The reduced light peak in patients is discussed extensively but the question remains -- is the calcium activated chloride current measured in the present study the in vivo LP response of the RPE? The authors state: \"Our results provide definitive evidence that the CaCC activity of *Best1*\"

• It would be important to know if the Cl channel currents (e.g. [Figure 1](#fig1){ref-type="fig"}) attributed to *Best1* can be pharmacologically blocked by appropriately specific inhibitors at the basolateral (or apical) membranes. The blocker specificity of NFA ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) is assumed but it is variable from one system to the next. For example, in native bovine RPE NFA increases basolateral membrane Cl conductance and the resultant Cl current is blocked by basal DIDS as measured by intracellular recording and by decreased 36Cl flux. In bovine RPE intracellular Cl was significantly decreased by NFA. By comparison, the current authors (Moshfegh et al., 2016) showed that elevated Ca (physiological?) also decreased intracellular Cl activity in iPSC-derived RPE as inferred from the initial decrease in measured YFP fluorescence. In the latter experiments the intracellular Ca increase could be acting at the plasma membrane or at locations inside the cell and the change in Cl activity could for example be mediated by apical membrane Na/K/2Cl cotransporters, or basolateral membrane HCO~3~/Cl exchangers (but see 4 below), or other Ca-mediated transporters/channels. It would be worthwhile measuring the intracellular Cl activities (YFP) in the presence and absence of NFA. It would be quite useful to provide a calibration for the Cl activity baseline and subsequent Ca-induced changes for the cells used in the present study (e.g. Watts et al. PLoS ONE 2012).

4\) Also, in the present experiments, the use of HEPES buffer (subsection "Electrophysiology", first paragraph) is an impediment to understanding how these responses might be connected to in vivo or in vitro LP responses (https://www.ncbi.nlm.nih.gov/pubmed/7153919). The absence of HCO~3~ buffer significantly deactivates a variety of apical and basolateral membrane transporters that control cell pH, Na, Cl, K, and volume in and around the RPE. For example, the apical membrane NaHCO~3~ co-transporter is electrogenic and if absent from these cells would reduce apical and basolateral membrane potential potentials, ion gradient\'s, and volume regulation and alter net fluid transport. These outcomes would obscure the possible connection between Ca-dependent currents measured in vitro and the in vivo events following light onset and the subsequent generation of the LP.

5\) Authors do not provide mechanistic evidence regarding the driving forces that generate the calcium activated chloride channel. Is it calcium from internal stores (ER, melanosomes, mitochondria?) or is it external calcium? What happens if the apical membrane L-type calcium channels are blocked? What happens if ER calcium is dumped and reuptake inhibited prior to recording?

6\) As noted by the authors most of the *BEST1* mutations are dominant. The measurement of aberrant Ca-dependent Cl current in RPE from that prevalent cohort of patents should also have been a priority. The authors showed that the two ARB patients they studied have significantly altered ERG a- and b-waves, indicating that the retinal input to generate the RPE LP is very likely abnormal. In contrast, autosomal dominant Best Vitelliform Macular Dystrophy (BVMD) patients exhibit normal ERGs and thus subsequent abnormal RPE LP can be more clearly analyzed in terms of RPE-specific abnormalities.

7\) One area of focus going forward could involve the ATP-induced activation of RPE apical membrane purinergic receptors that significantly increase cell calcium levels, and basolateral membrane Cl transport mediated fluid transport across the RPE. Activation of apical membrane alpha1 adrenergic receptors produces a similar sequence of events. A comparison of Ca-activated Cl currents in iPS-derived RPE from patients with recessive and dominant mutations relative to WT may provide a basis for functionally distinguishing these two genetically different types of patient.

Possible title modification: Characterization of Bestrophin1- mediated calcium activated chloride currents in human RPE.

9\) Karyotyping, iPSC characterization, and iPSC-RPE validation data information (beyond RPE65 and CRALBP in iPSC-derived RPE) -- should be included in text. Please specify the passage number for primary cultures of human fetal RPE.

10\) In the manuscript, please provide sequencing information that verifies the original mutation after reprogramming into iPSC and differentiation into RPE.

11\) IPSC were differentiated at passage 4. What criteria were used to ensure the stability of lines prior to differentiation?

*Reviewer \#3:*

This is an impressive study that addresses a long-standing question in the ion channel and visual science fields. Mutations in the Ca-activated Cl channel *BEST1* cause a spectrum of retinopathies known as bestrophinopathies, but the mechanisms have remained obscure at least partly because mouse models do not faithfully reproduce human. A hallmark of bestrophinopathies is the absence of the light peak in the electrooculogram. While it has long been suspected that *BEST1* is the channel responsible for the light peak, evidence has been lacking. This paper addresses the question by (1) identifying 2 patients with *BEST1* mutations and characterizing their phenoptype, (2) showing that RPE cells differentiated from iPSCs derived from these bestrophinopathy patients have defective Ca-activated Cl currents, (3) showing that HEK cells expressing the patient mutations have defective Cl currents, and (4) solving the crystal structure of a *BEST1* homolog (KpBest) with one of the patient mutations and recording single channel currents. This very powerful combination of approaches provides a strong argument that *BEST1* is the Ca-activated Cl channel responsible for the light peak.

Despite the strength of the multi-dimensional approach, each aspect of the study has serious weaknesses.

1\) The evidence that the ionic currents in iPSC-RPE cells that are interpreted as encoded by *BEST1* is weak. First, the current traces have the characteristic unmistakable appearance of volume-regulated anion channels (VRAC) and they do not resemble hBEST1 currents expressed in HEK cells (as can be seen comparing [Figure 1B](#fig1){ref-type="fig"} and [Figure 5A](#fig5){ref-type="fig"}). This could mean that the currents are mediated VRAC (LRRC8) which are somehow regulated by *BEST1*. Second, the experiments the authors perform to conclude these are *BEST1* currents are superficial. There is no data in this paper showing their anion selectivity. The use of NFA as a Ca-activated Cl channel blocker is bogus: NFA is more potent at blocking VRAC and TMEM16A than *BEST1* (PMID:28620305;PMID:25078708). The authors must rule out the possibility that the currents they are studying are VRAC currents. This could involve knockdown of LRRC8A. Another approach to distinguish between VRAC and *BEST1*, the authors might measure taurine permeability (taurine is zwitterionic so taurine currents can be measured at the appropriate pH). This is a crucial point. The authors might argue that VRAC is not Ca-activated, but VRAC is clearly Ca-regulated.

2\) The immunofluorescence images showing *BEST1* on the cell surface are not convincing. In [Figure 1A](#fig1){ref-type="fig"} and [2A](#fig2){ref-type="fig"}, ZO-1 is clearly on the cell surface, but most of *BEST1* is intracellular. It is not clear that any *BEST1* co-localizes with ZO-1. The authors must use deconvolution or super-resolution imaging and perform statistical analysis to show co-localization. This should be supplemented with cell surface biotinylation. Also, because the CaCC that generates the light peak is presumed to be on the basolateral membrane, the authors should determine whether *BEST1* is trafficked properly in these cultures. In [Figure 4B](#fig4){ref-type="fig"} the localization of *BEST1* is not obviously different from control. The level of expression seems spotty in the P274R mutant, but some cells look like they express at control levels. ZO-1 is very clearly disrupted in the I201T mutant, but the authors do not comment on this. It is also curious that overexpressed *BEST1* localizes more strongly to the plasma membrane than does the endogenous protein detected by antibody. This raises questions about the validity of the antibody. Has it been knockout-verified in IF?

3\) While the homology model is informative, the crystal structure of the KpBest L177T mutant does not provide any important insights. The KpBest L177T mutant is meant to model the hBEST1 I201T mutant. Not only is the mutated residue non-identical but of the 10 amino acids on either side of L177 (residues 167-187) only 3 amino acids are identical and not many more are structurally similar. Furthermore, KpBest is not a Cl channel, but a cation channel. It is puzzling why the authors did not use chicken *BEST1,* which has also been successfully crystalized and is very closely related to hBEST1. The shift in the helices shown in [Figure 8](#fig8){ref-type="fig"} does not obviously provide any mechanistic insights. A more detailed analysis of the effects of this mutation on the channel pore is required, but since this is a cation channel, I am not sure that the conclusions would be relevant. The single channel analysis supports the authors\' conclusions but would be more valuable if they were performed with cBest1. How many times was this experiment repeated?

4\) No methods are provided about how the ERGs were measured. How long were patients dark-adapted? What was the light stimulus intensity/duration, etc.? More explanation is required about the \"age-matched controls\". Were the controls measured co-temporaneously and how were they selected? Although the literature is a little ambiguous about ERG changes with age, I am a little surprised that normal teenagers have b-waves twice as large as a normal 72-year old. Not only should the authors provide more information about their own controls, but should compare their results to the published literature. At least one study shows no difference in b-wave amplitude between 20-39 year-olds and 60-82 year-olds (Doc Ophthalmol (2011) 122: 177.)

5\) Of the two mutations studied, the P274R is clearly the most dramatic. However, the impact of the cellular data are weakened because there are no electro-oculogram data presented for this patient. The authors should show current traces for the rescued cells and should show that the rescued currents have the same Ca sensitivity as WT. While the authors state that \"all patients display reduced LP\", it is not clear exactly what this means. There are cases in the literature describing patients with *BEST1* mutations that have normal LPs.

6\) In most experiments, only 4-5 cells were tested. Were these cells all from the same RPE colony derived from the same iPSC culture, or are they from different RPE colonies? If these data are from a single colony, how can one be certain that the difference in ionic currents is not explained by technical differences between colonies?

10.7554/eLife.29914.028

Author response

> 1\) Potential variability among different cell lines from the same donor -- i.e. how reproducible are the data obtained from different cell lines?

We appreciate the concern about potential variability among different cell lines from the same donor. We have now included additional clones for the WT and I201T mutant in the new [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. In both cases, the Ca^2+^-dependent Cl^-^ current amplitudes in two distinct clonal iPSC-RPEs from the same donor are next to identical, indicating the reproducibility and reliability of our data. We currently do not have mature P274R iPSC-RPE cells from a second clone. As the maturation time of iPSC-RPE varies from clone to clone, we are uncertain when an additional P274R iPSC-RPE line(s) may become available for testing within the next few months. As an alternative, we have now included data from P274R iPSC-RPE generated by a different set of differentiation in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}, which displayed consistent results.

> 2\) The distinction between Best1 current and other non-Best1 currents (e.g. VRAC) -- i.e. a fuller characterization of the rescued current.

We have now included the rescued current amplitude in P274R iPSC-RPE cells across a range of \[Ca^2+^\]~i~ in [Figure 4E and a](#fig4){ref-type="fig"} rescued trace exemplar in the new [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}. The pattern of Ca^2+^ response was similar in WT and rescued P274R iPSC-RPEs (EC~50~ 455 nM vs. 446 nM, [Figure 4E](#fig4){ref-type="fig"}), the rescued current trace had the appearance of WT RPE endogenous current, and the rescued current was inhibited by NFA to a similar level as the WT RPE endogenous current, indicating that the recorded currents in WT and rescued P274R iPSC-RPEs are both Ca^2+^-dependent Cl^-^ currents. This Ca^2+^-dependent Cl^-^ current is apparently dependent on BEST1, as the null phenotype in P274R iPSC-RPE was fully rescued by complementation with WT BEST1. As BEST1 is a Ca^2+^-activated Cl^-^ channel specifically expressed in the RPE surface, the simplest model according to the principle of Occam's Razor is that BEST1 conducts this Ca^2+^-dependent Cl^-^ current. This model is further supported by the direct correlation between the structural/functional deficiency of BEST1 channels and the severity of the clinical and cellular phenotypes. However, we cannot rule out the possibility that BEST1 somehow plays an indispensable role in regulating or cooperating with other anion channels such as TMEM16A, TMEM16B or other Ca^2+^-dependent VRAC. In fact, BEST1 itself has been suggested to function as a VRAC (Fischmeister and Hartzell, 2005; Qu and Hartzell, 2008). To conclusively exclude or include additional player(s) in mediating Ca^2+^-dependent Cl^-^ current in RPE, one needs to perform individual knockout of each candidate gene, which is beyond the scope of this work. The focus of this work is on Ca^2+^-dependent Cl^-^ current in RPE. VRAC current in RPE and the putative role of BEST1 as a VRAC are important but separate topics, which need to be carefully addressed in future studies.

> We appreciate that the reviewers\' comments cover a very broad range of suggestions for improving the manuscript. Please use your best judgment in deciding which of these can be accommodated in a reasonable period of time. We look forward to receiving your revised manuscript.
>
> Reviewer \#1:
>
> 1\) What are the differences in locations between the recessive mutations and dominant mutations in Bestrophin 1? Can the structural model predict or make sense of this functional difference? Since the data showed that the recessive mutants are still expressed at the protein level, it is surprisingly that the mutant subunit does not interfere with the function of the wild-type subunits in the pentamer (it does, it would be a dominant mutant).

Mutations causing ARB are mostly located outside of the exons that usually harbor vitelliform macular dystrophy--associated dominant mutations (Fung et al., 2015). Unfortunately, it is still hard to predict the functional differences between dominant and recessive mutations based on their locations on the structural model. For the P274R mutation, our immunostaining results showed that the mutant protein is not localized on the plasma membrane, suggesting that the mutant subunit cannot traffic onto the plasma membrane to interfere with the WT subunit. For the I201T mutation, as the structural alteration is subtle even in the mutant homopentamer ([Figure 8](#fig8){ref-type="fig"}), it may require certain numbers of I201T mutant protomers in the heteropentamers to cause a significant phenotype in the channel function. Moreover, whether or not I201T mutant protomers can be properly assembled to form heteropentamers with WT protomers is unknown.

> 2\) The authors write \"in any case, our results do not exclude the role of TMEM16A/TMEM16B in regulating Ca^2+^-dependent Cl^-^ current in human RPE.\" However, the authors presented data showing that RPE cells with the mutant Bestrophin 1 lacks any Ca^2+^-dependent Cl^-^ current. This data does exclude the role of TMEM16A/TMEM16B in regulating Ca^2+^-dependent Cl^-^ current in human RPE.

We agree with the reviewer that our results indicate an indispensable role of BEST1 in mediating Ca^2+^-dependent Cl^-^ current in human RPE. As we stated in response to major question \#2, the idea that BEST1 conducts this current, independent of any other channels, fits well with the principle of Occam's Razor. However, we cannot officially rule out the possibility that BEST1 somehow cooperates with or regulates other Ca^2+^-regulated Cl^-^ channels (e.g. TMEM16A, TMEM16B or Ca^2+^-dependent VRAC). We have revised the manuscript: "our results do not completely exclude the role of other CaCCs in contributing to Ca^2+^-dependent Cl^-^ current in human RPE".

> 3\) The authors state \"most of the BEST1 patient-specific mutations are dominant, so that the mutant BEST1 alleles in these cases may be gain-of-function as oppose to the loss-of-function alleles in ARB patients.\" There is only evidence to suggest that the dominant mutations are loss-of-function mutations. Is there any evidence that the dominant mutations cause a gain of function? This is also related to discussion point 1 above.

We thank the reviewer for pointing this out. We have revised this sentence to "... so that the mutant *BEST1* alleles in these cases may be more functionally defective and/or structurally disruptive compared to recessive mutant alleles in ARB patients."

> 4\) This study\'s demonstration that Bestrophin 1 is responsible for the calcium-dependent chloride current in human RPE cells makes sense physiologically and clinically given the fact that EOG is used routinely as a clinical tool to detect Best disease in human patients. Can the authors explain the difficulty to demonstrate this activity in mouse models and the lessons that can be learned on drawing conclusions using mouse models, which are still the most common used models?

There are significant species-specific differences between mouse and human RPE cells. For instance, only 3% of human RPE cells are binucleate, in contrast to 35% in mice (Volland et al., 2015). In regard to mutation-caused retinal diseases, the differences between these two species are even more obvious. Besides *BEST1*, defects in the *TIMP3* and *EFEMP1* genes both cause much more severe eye phenotypes in humans as compared to knockout/knock-in mice. We agree with the reviewer that conclusions should be drawn with cautions on the differences between species and the advantages/limitations of different experimental systems.

> Reviewer \#2:
>
> 1\) N=1 Patient iPSC-RPE I201T (mild phenotype), N=1 Patient iPSC-RPE P274R (extreme phenotype). These findings should be replicated using more clones per iPSC line. Low N number cannot mitigate donor/clonal variability, which has been seen to be quite high in patient and control iPSC samples.

Please refer to response to major question \#1.

> 2\) The authors state: \"Here for the first time, we directly measured Ca^2+^- dependent Cl currents on the plasma membrane of human RPEs by whole-cell patch clamp\" This statement raises a critical question: Where is Best1 localized \"on the plasma membrane\" in these human RPEs?
>
> • Is it the apical or basolateral membrane? The authors stain for ZO-1 and Best1, but ZO1 is an apical membrane marker. Immunostaining is low resolution, but it shows that BEST1 does not co-localize with ZO1. It seems cytoplasmic. Authors can rule out cytoplasmic localization using ER and Endosome markers. In other systems, basolateral localization is indicated (Johnson et al., 2017). Typical apical membrane markers for human RPE are ezrin or N/K ATPase and collagen IV is a marker for the basolateral membrane.

As the reviewer suggested, we co-stained BEST1 with the endosome marker EEA1. The results show that BEST1 does not co-localize with EEA1 ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}), ruling out the cytoplasmic localization of BEST1. We agree that it is critical to determine whether BEST1 localizes on the apical or basal membrane in human RPE. However, in our system, RPE cells are directly attached to the culturing dish, so that the polarity of the cells may not best represent the status of RPE cells in vivo where supporter cells and a more sophisticated 3-D environment are present. Consistent with this notion, we have tried to use collagen IV as a basolateral membrane marker to stain our RPE culture, but the result was unclear. Overall, we can only conclude that BEST1 is localized on the plasma membrane of human RPE cells in our system, but cannot further distinguish between apical and basolateral localizations. We are excited to investigate this question in follow-up studies under more physiological conditions such as in vitro 3-D RPE cultures.

> 3\) The reduced light peak in patients is discussed extensively but the question remains -- is the calcium activated chloride current measured in the present study the in vivo LP response of the RPE? The authors state: \"Our results provide definitive evidence that the CaCC activity of Best1\"
>
> • It would be important to know if the Cl channel currents (e.g. [Figure 1](#fig1){ref-type="fig"}) attributed to Best1 can be pharmacologically blocked by appropriately specific inhibitors at the basolateral (or apical) membranes. The blocker specificity of NFA ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) is assumed but it is variable from one system to the next. For example, in native bovine RPE NFA increases basolateral membrane Cl conductance and the resultant Cl current is blocked by basal DIDS as measured by intracellular recording and by decreased 36Cl flux. In bovine RPE intracellular Cl was significantly decreased by NFA. By comparison, the current authors (Moshfegh et al., 2016) showed that elevated Ca (physiological?) also decreased intracellular Cl activity in iPSC-derived RPE as inferred from the initial decrease in measured YFP fluorescence. In the latter experiments the intracellular Ca increase could be acting at the plasma membrane or at locations inside the cell and the change in Cl activity could for example be mediated by apical membrane Na/K/2Cl cotransporters, or basolateral membrane HCO~3~/Cl exchangers (but see 4 below), or other Ca-mediated transporters/channels. It would be worthwhile measuring the intracellular Cl activities (YFP) in the presence and absence of NFA. It would be quite useful to provide a calibration for the Cl activity baseline and subsequent Ca-induced changes for the cells used in the present study (e.g. Watts et al. PLoS ONE 2012).
>
> 4\) Also, in the present experiments, the use of HEPES buffer (subsection "Electrophysiology", first paragraph) is an impediment to understanding how these responses might be connected to in vivo or in vitro LP responses (https://www.ncbi.nlm.nih.gov/pubmed/7153919). The absence of HCO~3~ buffer significantly deactivates a variety of apical and basolateral membrane transporters that control cell pH, Na, Cl, K, and volume in and around the RPE. For example, the apical membrane NaHCO~3~ co-transporter is electrogenic and if absent from these cells would reduce apical and basolateral membrane potential potentials, ion gradient\'s, and volume regulation and alter net fluid transport. These outcomes would obscure the possible connection between Ca-dependent currents measured in vitro and the in vivo events following light onset and the subsequent generation of the LP.
>
> 5\) Authors do not provide mechanistic evidence regarding the driving forces that generate the calcium activated chloride channel. Is it calcium from internal stores (ER, melanosomes, mitochondria?) or is it external calcium? What happens if the apical membrane L-type calcium channels are blocked? What happens if ER calcium is dumped and reuptake inhibited prior to recording?
>
> 6\) As noted by the authors most of the BEST1 mutations are dominant. The measurement of aberrant Ca-dependent Cl current in RPE from that prevalent cohort of patents should also have been a priority. The authors showed that the two ARB patients they studied have significantly altered ERG a- and b-waves, indicating that the retinal input to generate the RPE LP is very likely abnormal. In contrast, autosomal dominant Best Vitelliform Macular Dystrophy (BVMD) patients exhibit normal ERGs and thus subsequent abnormal RPE LP can be more clearly analyzed in terms of RPE-specific abnormalities.
>
> 7\) One area of focus going forward could involve the ATP-induced activation of RPE apical membrane purinergic receptors that significantly increase cell calcium levels, and basolateral membrane Cl transport mediated fluid transport across the RPE. Activation of apical membrane alpha1 adrenergic receptors produces a similar sequence of events. A comparison of Ca-activated Cl currents in iPS-derived RPE from patients with recessive and dominant mutations relative to WT may provide a basis for functionally distinguishing these two genetically different types of patient.

We thank the reviewer for instructive comments on our work and future directions. As the reviewer kindly pointed out, there are still many crucial subjects awaiting further investigation in this field (e.g. pharmacological blockage of LP-related Cl^-^ channels, the in vivo network for the generation of LP, the driving force of CaCCs, the difference of RPE-specific abnormalities between patients with *BEST1* dominant and recessive mutations, etc.). These are all important and interesting topics that we are following up with.

> 8\) Possible title modification: Characterization of Bestrophin1- mediated calcium activated chloride currents in human RPE.

We thank the reviewer for the suggestion. As the main conclusions of our work were based on results from patient-derived RPE cells with two distinct *BEST1* mutations, we have integrated the reviewer's advice and changed the title to "Patient-Specific Mutations Impair BESTROPHIN1's Essential Role in Mediating Ca^2+^-Dependent Cl^-^ Currents in Human RPE."

> 9\) Karyotyping, iPSC characterization, and iPSC-RPE validation data information (beyond RPE65 and CRALBP in iPSC-derived RPE) -- should be included in text. Please specify the passage number for primary cultures of human fetal RPE.

As the reviewer suggested, we have now included karyotyping, iPSC characterization and iPSC-RPE validation information in the manuscript ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, subsections "Generation of human iPSC" and "Differentiation iPSC into RPE"). All the fetal RPE and iPSC-RPE cells used in this study were at their passage 1 (added in subsection "Differentiation iPSC into RPE" and "Fetal human RPE isolation and culture").

> 10\) In the manuscript, please provide sequencing information that verifies the original mutation after reprogramming into iPSC and differentiation into RPE.

Verification of the original mutations in iPSC-RPEs by sequencing has been added in the subsection "Differentiation iPSC into RPE".

> 11\) IPSC were differentiated at passage 4. What criteria were used to ensure the stability of lines prior to differentiation?

We closely monitored the morphology and nuclear/cytoplasmic ratio of our iPSC lines to ensure the stability of them. Please see the newly added [Figure 1‒figure supplement 1A](#fig1s1){ref-type="fig"}, showing the representative phase picture of iPSC right before differentiation.

> Reviewer \#3:
>
> 1\) The evidence that the ionic currents in iPSC-RPE cells that are interpreted as encoded by BEST1 is weak. First, the current traces have the characteristic unmistakable appearance of volume-regulated anion channels (VRAC) and they do not resemble hBEST1 currents expressed in HEK cells (as can be seen comparing [Figure 1B](#fig1){ref-type="fig"} and [Figure 5A](#fig5){ref-type="fig"}). This could mean that the currents are mediated VRAC (LRRC8) which are somehow regulated by BEST1. Second, the experiments the authors perform to conclude these are BEST1 currents are superficial. There is no data in this paper showing their anion selectivity. The use of NFA as a Ca-activated Cl channel blocker is bogus: NFA is more potent at blocking VRAC and TMEM16A than BEST1 (PMID:28620305;PMID:25078708). The authors must rule out the possibility that the currents they are studying are VRAC currents. This could involve knockdown of LRRC8A. Another approach to distinguish between VRAC and BEST1, the authors might measure taurine permeability (taurine is zwitterionic so taurine currents can be measured at the appropriate pH). This is a crucial point. The authors might argue that VRAC is not Ca-activated, but VRAC is clearly Ca-regulated.

Please refer to responses to major question \#2 and reviewer 1's question \#2. Moreover, the differences between native currents in RPE and BEST1 currents expressed in HEK293 cells are likely attributed to the intrinsic differences between the two hosting cell types.

> 2\) The immunofluorescence images showing BEST1 on the cell surface are not convincing. In [Figure 1A](#fig1){ref-type="fig"} and [2A](#fig2){ref-type="fig"}, ZO-1 is clearly on the cell surface, but most of BEST1 is intracellular. It is not clear that any BEST1 co-localizes with ZO-1. The authors must use deconvolution or super-resolution imaging and perform statistical analysis to show co-localization. This should be supplemented with cell surface biotinylation. Also, because the CaCC that generates the light peak is presumed to be on the basolateral membrane, the authors should determine whether BEST1 is trafficked properly in these cultures. In [Figure 4B](#fig4){ref-type="fig"} the localization of BEST1 is not obviously different from control. The level of expression seems spotty in the P274R mutant, but some cells look like they express at control levels. ZO-1 is very clearly disrupted in the I201T mutant, but the authors do not comment on this. It is also curious that overexpressed BEST1 localizes more strongly to the plasma membrane than does the endogenous protein detected by antibody. This raises questions about the validity of the antibody. Has it been knockout-verified in IF?

We co-stained BEST1 with the endosome marker EEA1. The results show that BEST1 does not co-localize with EEA1 ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}), ruling out the cytoplasmic localization of BEST1. We agree that the basolateral vs. apical membrane localization of BEST1 will need further investigation. Please refer to our response to reviewer 2's question \#2. In [Figure 4B](#fig4){ref-type="fig"}, the upper panel is P274R, which lost the membrane enrichment, while the bottom panel is I201T, which was not different from the WT control. The P274R mutant lost membrane enrichment, but the protein expression level was similar as the WT control ([Figure 4A](#fig4){ref-type="fig"}). Although we do not have a *BEST1* knockout RPE, there is no BEST1 immunoreactivity in RPE derived from WT iPSC until sufficient RPE maturation. It is challenging to compare antibody staining of endogenous BEST1 and fluorescently labelled exogenous BEST1 directly, especially because the former experiment was performed with hexagonally shaped, tight junction-connected RPEs which had been cultured in the same dish for over a month, while the latter was in freshly seeded RPEs which had not reformed the typical hexagonal shape and intercellular tight junctions.

> 3\) While the homology model is informative, the crystal structure of the KpBest L177T mutant does not provide any important insights. The KpBest L177T mutant is meant to model the hBEST1 I201T mutant. Not only is the mutated residue non-identical but of the 10 amino acids on either side of L177 (residues 167-187) only 3 amino acids are identical and not many more are structurally similar. Furthermore, KpBest is not a Cl channel, but a cation channel. It is puzzling why the authors did not use chicken BEST1, which has also been successfully crystalized and is very closely related to hBEST1. The shift in the helices shown in [Figure 8](#fig8){ref-type="fig"} does not obviously provide any mechanistic insights. A more detailed analysis of the effects of this mutation on the channel pore are required, but since this is a cation channel, I am not sure that the conclusions would be relevant. The single channel analysis supports the authors\' conclusions but would be more valuable if they were performed with cBest1. How many times was this experiment repeated?

Although cBest1 has a higher sequence identity with human BEST1 compared to KpBest, the two structures are very similar. Both KpBest and cBest1 are pentamers displaying a flower vase shaped ion permeation pathway with two narrow hydrophobic restrictions. Here, we used both KpBest crystal structures and cBest1 based human homology models to analyze the possible structural alterations in human BEST1 caused by the patient-specific mutations. Results from the two methods are consistent with each other, and supported by functional data. The bilayer results were from 3 independent experiments as indicated now in figure legends. Unfortunately, we currently do not have the capacity to purify cBest1.

> 4\) No methods are provided about how the ERGs were measured. How long were patients dark-adapted? What was the light stimulus intensity/duration, etc.? More explanation is required about the \"age-matched controls\". Were the controls measured co-temporaneously and how were they selected? Although the literature is a little ambiguous about ERG changes with age, I am a little surprised that normal teenagers have b-waves twice as large as a normal 72-year old. Not only should the authors provide more information about their own controls, but should compare their results to the published literature. At least one study shows no difference in b-wave amplitude between 20-39 year-olds and 60-82 year-olds (Doc Ophthalmol (2011) 122: 177.)

We used international standardized procedures to carry out the ERG (Kohl et al., 2015; McCulloch et al., 2015), and have included these two references in the manuscript (cited in the subsection "Patients and clinical analysis"). Following 10 minutes of light adaptation, the photopic 30-Hz flicker cone and transient photopic cone ERGs were recorded. A stimulus 0.6 log units greater than the ISCEV standard flash was also used to better demonstrate the a-wave, as suggested in the recent revision of the ISCEV standard for ERG. Subjects were dark-adapted for thirty minutes (ISCEV standards are at least twenty minutes). Autosomal recessive bestrophinopathy is a form of progressive generalized rod-cone dystrophy, and hence maximal ERG b-waves are expected to be lower in the 72-year-old affected subject. Control subjects were not measured contemporaneously with the patients. Our initial submission provided representative traces from exactly age-matched normal subjects in our routine clinic. As ERG results are sensitive to the setups and conditions of the measuring devices, it is more accurate to compare subjects measured in the same practice. We have revised the manuscript to "... contrasting 355 μV (median value) in healthy teenagers tested in the same device", and "... contrasting 287 μV (median value) in age matched healthy people", respectively.

> 5\) Of the two mutations studied, the P274R is clearly the most dramatic. However, the impact of the cellular data are weakened because there are no electro-oculogram data presented for this patient. The authors should show current traces for the rescued cells and should show that the rescued currents have the same Ca sensitivity as WT. While the authors state that \"all patients display reduced LP\", it is not clear exactly what this means. There are cases in the literature describing patients with BEST1 mutations that have normal LPs.

The rescued current traces and the Ca^2+^-sensitivity are now shown in the new [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Figure 4E](#fig4){ref-type="fig"}. As the patient with the milder I201T mutation has no EOG light rise, we do not expect the patient with the more severe P274R mutation to have it. Furthermore, we would have trouble getting this patient's EOG data on time for the paper resubmission because his insurance is not accepted by the hospital and he lives far from our location. Normal LPs in patients with *BEST1* mutations have never been seen in recessive cases, and they have been very rare for dominant cases. Both of our patients in this study are recessive. To address the reviewer's concern, we have revised the sentence to "... reduced LP is a clinical feature in *BEST1* patients".

> 6\) In most experiments, only 4-5 cells were tested. Were these cells all from the same RPE colony derived from the same iPSC culture, or are they from different RPE colonies? If these data are from a single colony, how can one be certain that the difference in ionic currents is not explained by technical differences between colonies?

We thank the reviewer for raising this concern. In our initial submission, 5-6 cells were tested for each patch clamp data point except for [Figure 4E](#fig4){ref-type="fig"}, in which 3-5 P274R cells were included for each data point. Because P274R cells had no current at all tested \[Ca^2+^\]s, the variance between cells were extremely small, allowing us to draw a statistically significant conclusion with fewer cells. Moreover, we have now included more samples from different clones and/or differentiations in the new [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. Please refer to the response to major question \#1.

[^1]: These authors contributed equally to this work.
